The Lancet: Dangerous HabitsEditorial
3 years ago, a Lancet editorial began, "The smoking of cannabis, even long term, is not harmful to health" (Nov 11, 1995); an assertion criticised by many readers as encouraging an indulgence that is illegal in many countries. Predictably, the legalise-cannabis lobby seized on The Lancet's apparent endorsement of this substance's safety. This week we publish a seminar on the adverse effects of cannabis (p 1611) . Wayne Hall and Nadia Solowij conclude that the most likely adverse effects of smoking cannabis are bronchial irritation, the risk of accidents when intoxicated, dependence, and possible cognitive impairment with heavy, long-term use. The evidence summarised in this seminar was considered by a committee of the UK House of Lords which reported on Nov 11 . The committee recommended that clinical trials be done on the effects of cannabis in multiple sclerosis and in chronic pain, and that the UK Government should reclassify cannabis so that it can be prescribed by doctors under certain circumstances.
The debate about whether or not cannabis, taken for recreational rather than medical reasons, should be legalised in countries where it is banned will rumble on, and further complicate scientific assessment of the therapeutic effects of cannabinoids. The arguments advanced by each side are well-rehearsed, but usually fail to consider the problems presented by cannabis in a wider perspective. We would, perhaps, have been wiser to have begun our editorial 3 years ago with a less provocative statement; but, on the evidence summarised by Hall and Solowij, it would be reasonable to judge cannabis less of a threat to health than alcohol or tobacco, products that it many countries are not only tolerated and advertised but are also a useful source of tax revenue. The desire to take mood-altering substances is an enduring feature of human societies worldwide and even the most draconian legislation has failed to extinguish this desire--for every substance banned another will be discovered, and all are likely to have some ill-effect on health. This should be borne in mind by social legislators who, disapproving of other people's indulgences, seek to make them illegal. Such legislation does not get rid of the problem; it merely shifts it elsewhere.
One aspect of taking mood-altering substances may require legislation: the protection of others from annoyance and harm. Whether or not a person's indulgence poses a threat to others has been used as a guide to define the limits of socially acceptable behaviour; although to do so begs the question of people's responsibility for themselves. Should it be, for example, permissible for people deliberately to put their lives or health at risk through participating in dangerous sports such as boxing or motor racing? Do people have the right to decide for themselves what risks to take, irrespective of any expense and inconvenience to others when the risks come home? Is it reasonable to say "It is my life, I shall do as I choose", when almost everyone shares their lives with friends or family who would be damaged by their illness or death? Whatever the answers to these questions, there is one aspect that is indisputable: people have the right to know what are the risks to themselves and to others.
2 weeks ago, we published evidence that the sustained use of 3,4-methylenedioxymethamphetamine ("Ecstasy") was associated with a decrease in serotonin neurons in the brain (Oct 31, p 1433) . This is information that any user of Ecstasy has a right to know; just as users of cannabis should be aware of its possible hazards. Because the debate about use of cannabis arouses strong emotions, there is, as Hall and Solowij note, no "consensus on what health information the medical profession should give to patients who are users or potential users of cannabis." Doctors called upon for advice about use of cannabis will find the authors' last paragraph a useful source of dispassionate information. The advice is little different from that appropiate for many other mood-altering substances: do not drive motor vehicles whilst intoxicated and do not overindulge.
We will qualify our opinion of 3 years ago and say that, on the medical evidence available, moderate indulgence in cannabis has little ill-effect on health, and that decisions to ban or to legalise cannabis should be based on other considerations.
Pubdate: Sat, 14 Nov 1998 Source: Lancet, The (UK) Volumne: 352, Number 9140 Contact: firstname.lastname@example.org Website: http://www.thelancet.com/
National Drug and Alcohol Research Centre,
Cannabis The Drug
ADVERSE EFFECTS OF CANNABIS
Cannabis is the most widely used illicit drug in many developed societies. Its health and psychological effects are not well understood and remain the subject of much debate, with opinions on its risks polarised along the lines of proponents' views on what its legal status should be. An unfortunate consequence of this polarisation of opinion has been the absence of any consensus on what health information the medical profession should give to patients who are users or potential users of cannabis. There is conflicting evidence about many of the effects of cannabis use, so we summarise the evidence on the most probable adverse health and psychological consequences of acute and chronic use. This uncertainty, however, should not prevent medical practitioners from advising patients about the most likely ill-effects of their cannabis use. Here we make some suggestions about the advice doctors can give to patients who use, or are contemplating the use, of this drug.
In many western societies, cannabis has been used by a substantial minority, and in some a majority, of young adults, even though its use is prohibited by law.1 Debate about the justification for continuing to prohibit cannabis use has polarised opinion about the seriousness of its adverse health effects.2 In addition, the possible therapeutic effects of cannabinoids have become entangled in the debate about prohibition of recreational cannabis use (see Further reading). The health effects of cannabis use, especially of long-term use, remain uncertain because there is very little epidemiological research and because of disagreements about the interpretation of the limited epidemiological and laboratory evidence.2 Here we summarise the evidence on the most probable adverse health effects of cannabis use acknowledging where appropriate the uncertainty that remains.
CANNABIS THE DRUG
Cannabis preparations are largely derived from the female plant of Cannabis sativa. The primary psychoactive constituent is δ-9-tetrahydrocannabinol (THC).3 The THC content is highest in the flowering tops, declining in the leaves, lower leaves, stems, and seeds of the plant. Marijuana (THC content 0,5-5,0%) is prepared from the dried flowering tops and leaves; hashish (THC content 2-20%) consists of dried cannabis resin and compressed flowers; and hashish oil may contain between 15% and 50% THC.3 Sinsemilla and Netherwood varieties of cannabis may have a THC content of up to 20%.3 Cannabis may be smoked in a "joint", which is the size of a cigarette, or in a water pipe. Tobacco may be added to assist burning. Smokers typically inhale deeply and hold their breath to maximise absorption of THC by the lungs. Marijuana and hashish may also be eaten, but cannabis is mostly smoked because this is the easiest way to achieve the desired psychoactive effects.2
A typical joint contains between 0.5 g and 1.0 g of cannabis. The THC delivered varies between 20% and 70%,2 its bioavailability ranging from 5% to 24%.3 As little as 2-3 mg of available THC will produce a "high" in occasional users, but regular users may smoke five or more joints a day.
Cannabinoids act on a specific receptor that is widely distributed in the brain regions involved in cognition, memory reward, pain perception, and motor coordination.3 These receptors respond to an endogenous ligand, anandamide, which is much less potent and has a shorter duration than THC.3 The identification of a specific cannabinoid antagonist promises to improve our understanding of the role of cannabinoids in normal brain function.3
PATTERNS OF CANNABIS USE
Cannabis has been tried by many European young adults and by most young adults in the USA and Australia.1 Most cannabis use is intermittent and time-limited: most users stop in their mid to late 20s, and very few engage in daily cannabis use over a period of years.4 In the USA and Australia, about 10% of those who ever use cannabis become daily users, and another 20-30% use the drug weekly.1,4
Because of uncertainties about THC content, heavy cannabis use is generally defined as daily or near daily use.2 This pattern of use over years places users at greatest risk of adverse health and psychological consequences.2 Daily cannabis users are more likely to be male, to be less well educated, to use alcohol and tobacco regularly, and to use amphetamines, hallucinogens, psychostimulants, sedatives, and opioids.5
ACUTE EFFECTS OF CANNABIS
Cannabis produces euphoria and relaxation, perceptual alterations, time distortion, and the intensification of ordinary sensory experiences, such as eating, watching films, and listening to music.2 When used in a social setting it may produce infectious laughter and talkativeness. Short-term memory and attention, motor skills, reaction time, and skilled activities are impaired while a person is intoxicated.2
The most common unpleasant side-effects of occasional cannabis use are anxiety and panic reactions.2 These effects may be reported by naïve users, and they are a common reason for discontinuation of use; more experienced users may occasionally report these effects after receiving a much larger than usual dose of THC.2
Cannabis smoking or ingestion of THC increases heart rate by 20-50% within a few minutes to a quarter of an hour; this effect lasts for up to 3 h.2 Blood pressure is increased while the person is sitting, and decreased while standing.2 These effects are of negligible clinical significance in healthy young users because tolerance develops to them.2
The acute toxicity of cannabinoids is very low.2 There are no confirmed published cases worldwide of human deaths from cannabis poisoning, and the dose of THC required to produce 50% mortality in rodents is extremely high compared with other commonly used drugs.2
Psychomotor effects and driving
Cannabis produces dose-related impairments in cognitive and behavioural functions that may potentially impair driving a motor vehicle or operating machinery.6 These impairments are larger and more persistent for difficult tasks that depend on sustained attention.6 The most serious possible consequence of acute cannabis use is a road-traffic accident if a user drives while intoxicated.2
The effects of recreational doses of cannabis on driving performance in laboratory simulators and standardised driving courses have been reported by some researchers as being similar to the effects when blood alcohol concentrations are between 0.07% and 0.10%.2 However, studies of the effects of cannabis on driving under more realistic conditions on roads have shown much more modest impairments,7,8 probably because cannabis users are more aware of their impairment and less inclined to take risks than alcohol users.7,8
Results of epidemiological studies of road-traffic accidents are equivocal because most drivers who have cannabinoids in their blood also have high blood alcohol concentrations.2 In two studies with reasonable numbers of individuals who had only used cannabis, there was no clear evidence of increased culpability in these drivers.9 The separate effects of alcohol and cannabis on psychomotor impairment and driving performance in laboratory tasks are roughly additive,9 so the main effect of cannabis use on driving may be in amplifying the impairments caused by alcohol, which is often used with the drug.2
EFFECTS OF CHRONIC CANNABIS USE
Cellular effects and the immune system Cannabis smoke may be carcinogenic; it is mutagenic in vitro and in vivo.10 Cannabinoids impair cell-mediated and humoral immunity in rodents, decreasing resistance to infection, and non-cannabinoids in cannabis smoke impair alveolar macrophages.11 The relevance of these findings to human health is uncertain because the doses of THC used in animal studies have been very high, and tolerance may develop to the effects on immunity in human beings.12
A few studies that have pointed to the adverse effects of cannabis on human
immunity have not been replicated.12 There is no conclusive evidence that
consumption of cannabinoids impairs human immune function, as measured by
numbers of T lymphocytes, B lymphocytes, or macrophages, or immunoglobulin
concentrations.12 Two prospective studies of HIV-positive homosexual men
have shown that cannabis use is not associated with an increased risk of
progression to AIDS concentrations.13,14
Summary of adverse effects of cannabis
* Anxiety and panic, especially in naïve users.
* Impaired attention, memory, and psychomotor performance while intoxicated.
* Possibly an increased risk of accident if a person drives a motor vehicle while intoxicated with cannabis, especially if cannabis is used with alcohol.
* Increased risk of psychotic symptoms among those who are vulnerable because of personal or family history of psychosis.
Chronic effects (uncertain but most probable)
* Chronic bronchitis and histopathological changes that may be precursors to the developmentof malignant disease.
* A cannabis dependence syndrome characterised by an inability to abstain from or to control cannabis use.
* Subtle impairments of attention and memory that persist while the user remains chronically intoxicated, and that may or may not be reversible after prolonged abstinence.
Possible adverse effects (to be confirmed)
* Increased risk of cancers of the oral cavity, pharynx, and oesophagus; leukaemia among offspring exposed in utero.
* Impaired educational attainment in adolescents and underachievement in adults in occupations requiring high-level cognitive skills.
Groups at higher risk of experiencing these adverse effects
* Adolescents with a history of poor school performance, who initiate cannabis use in the early teens, are at increased risk of using other illicit drugs and of becoming dependent on cannabis.
* Women who continue to smoke cannabis during pregnancy may increase their risk of having a low-birthweight baby.
* People with asthma, bronchitis, emphysema, schizophrenia, and alcohol and other drug dependence, whose illnesses may be exacerbated by cannabis use.
Chronic heavy cannabis smoking is associated with increased symptoms of chronic bronchitis, such as coughing, production of sputum, and wheezing.15,16 Lung function is significantly poorer and there are significantly greater abnormalities in the large airways of marijuana smokers than in non-smokers. Tashkin and colleagues16,17 have reported evidence of an additive effect of marijuana and tobacco smoking on histopathological abnormalities in lung tissue.
Bloom and colleagues15 reported similar additive effects on bronchitic symptoms in an epidemiological study of the respiratory effects of smoking "non-tobacco" cigarettes in 990 individuals aged under 40 years in Tucson, Arizona, USA. Non-tobacco smokers reported more coughing, phlegm production, and wheeze than non-smokers, irrespective of whether they also smoked tobacco. Those who had never smoked any substance had the best respiratory functioning, followed in order of decreasing function by current tobacco smokers, current non-tobacco smokers, and current smokers of both tobacco and non-tobacco cigarettes. Non-tobacco smoking alone had a larger effect on respiratory function than tobacco smoking alone, and the effect of both types of smoking was additive.15
In 1997, Tashkin and colleagues18 reported that the rate of decline in respiratory function over 8 years among marijuana smokers did not differ from that in non-smokers. This finding contrasted with that of a follow-up of the Tucson cohort,19 in which there was a greater rate of decline in respiratory function among marijuana-only smokers than in tobacco-only smokers and additive effects of tobacco and marijuana smoking. Both studies showed that long-term cannabis smoking increased bronchitic symptoms.
In view of the adverse effects of tobacco smoking, the similarity between tobacco and cannabis smoke, and the evidence that cannabis smoking produces histopathological changes that precede lung cancer,17 long-term cannabis smoking may also increase the risks of respiratory cancer.20 There have been reports of cancers in the aerodigestive tract in young adults with a history of heavy cannabis use.21,22 These reports are worrying since such cancers are rare among adults under the age of 60, even those who smoke tobacco and drink alcohol.20 Case-control studies of the role of cannabis smoking in these cancers are urgently needed.
Chronic administration of high doses of THC to animals lowers testosterone secretion, impairs sperm production, motility, and viability, and disrupts the ovulatory cycle.23 Whether cannabis smoking has these effects in human beings is uncertain because the published evidence is small and inconsistent.2
Cannabis administration during pregnancy reduces birthweight in animals.24 The results of human epidemiological studies have been more equivocal.2 The stigma of using illicit drugs during pregnancy discourages honest reporting,25 and when associations are found, they are difficult to interpret because cannabis users are more likely than non-users to smoke tobacco, drink alcohol, and use other illicit drugs during pregnancy, and they differ in social class, education, and nutrition.26 Several studies have suggested that cannabis smoking in pregnancy may reduce birthweight.2 In the best controlled of these studies, this relation has persisted after statistical control for potential confounding variables,27 but other studies28 have not shown any such association. The effect of cannabis on birthweight in the studies that have found an association has been small compared with that of tobacco smoking.26
That cannabis use during pregnancy increases the risk of birth defects is unlikely. Early case reports have not been supported by large well-controlled epidemiological studies. For example, the study by Zuckerman et al27 included a large sample of women with a substantial prevalence of cannabis use that was verified by urine analysis, and there was no increase in birth defects.
There is suggestive evidence that infants exposed in utero to cannabis have behavioural and developmental effects during the first few months after birth.26 Between the ages of 4 and 9 years, children who were exposed in utero have shown deficits in sustained attention, memory, and higher cognitive functioning.29 The clinical significance of these effects remains unclear since they are small compared with the effects of maternal tobacco use.29
Three studies have shown an increased risk of non-lymphoblastic leukaemia,30 rhabdomyosarcoma,31 and astrocytoma32 in children whose mothers reported using cannabis during their pregnancies. None of these was a planned study of the association; cannabis use was one of many potential confounders included in statistical analyses of the relation between the exposure of interest and childhood cancer. Their replication is a priority. Behavioural effects in adolescence
There is a cross-sectional association between heavy cannabis use in adolescence and the risk of leaving high-school education and of experiencing job instability in young adulthood.33 However, the strength of this association is reduced in longitudinal studies when statistical adjustments are made for the fact that, compared with their peers, heavy cannabis users have poor high-school performance before using cannabis.33,34 There is some evidence that heavy use has adverse effects on family formation, mental health, and involvement in drug-related crime.33 In each case, the strong associations in cross-sectional studies are more modest in longitudinal studies after statistical control for associations between cannabis use and other pre-existing characteristics that independently predict these adverse outcomes.34
A consistent finding in the USA has been the regular sequence of initiation into drug use in which cannabis use has typically preceded involvement with "harder" illicit drugs such as stimulants and opioids.5,33,35 The interpretation of this sequence remains controversial. The less compelling hypothesis is that cannabis use directly increases the use of other drugs in the sequence. There is better support for two other hypotheses--namely, that there is a selective recruitment into cannabis use of non-conforming adolescents who have a propensity to use other illicit drugs, and that once recruited to cannabis use, social interaction with drug-using peers, and greater access to illicit-drug markets, they are more likely to use other illicit drugs.2, 34
Animals develop tolerance to the effects of repeated doses of THC,36 and studies suggest that cannabinoids may affect the same reward systems as alcohol, cocaine, and opioids.37 Heavy smokers of cannabis also develop tolerance to its subjective and cardiovascular effects,36 and some report withdrawal symptoms on the abrupt cessation of cannabis use.36,38
There is evidence that a cannabis dependence syndrome occurs with heavy chronic use in individuals who report problems in controlling their use and who continue to use the drug despite experiencing adverse personal consequences.2,39 There is some clinical evidence of a dependence syndrome analogous to that for alcohol.2 In the USA, cannabis dependence is among the most common forms of illicit-drug dependence in the population.40 About one in ten of those who ever use cannabis become dependent on it at some time during their 4 or 5 years of heaviest use.40 This risk is more like the equivalent risk for alcohol (15%) than for nicotine (32%) or opioids (23%).40
The long-term heavy use of cannabis does not produce the severe or grossly debilitating impairment of memory, attention, and cognitive function that is found with chronic heavy alcohol use.2 Electrophysiological and neuropsychological studies show that it may produce more subtle impairment of memory, attention, and the organisation and integration of complex information.41-43 The longer cannabis has been used, the more pronounced the cognitive impairment.41 These impairments are subtle, so it remains unclear how important they are for everyday functioning, and whether they are reversed after an extended period of abstinence.2 Early studies that suggested gross structural brain damage with heavy use have not been supported by better controlled studies with better methods.41 Research in animals has shown that chronic cannabinoid administration may compromise the endogenous cannabinoid system3,41 (its function is unclear, but it has roles in memory, emotion, and cognitive functioning, as mentioned above). These results are consistent with the subtlety of the cognitive effects of chronic cannabis use in human beings.41
Large doses of THC produce confusion, amnesia, delusions, hallucinations, anxiety, and agitation.44 Such reactions are rare, occurring after unusually heavy cannabis use; in most cases they remit rapidly after abstinence from cannabis.2
There is an association between cannabis use and schizophrenia. A prospective study of 50 000 Swedish conscripts45 found a dose-response relation between the frequency of cannabis use by age 18 and the risk of a diagnosis of schizophrenia over the subsequent 15 years. A plausible explanation is that cannabis use can exacerbate the symptoms of schizophrenia,2,46 and there is prospective evidence that continued use predicts more psychotic symptoms in people with schizophrenia.47 A declining incidence of treated cases of schizophrenia over the period when cannabis use has increased suggests, however, that cannabis use is unlikely to have caused cases of schizophrenia that would not otherwise have occurred.48 This observation suggests that chronic use may precipitate schizophrenia in vulnerable individuals, an effect that would not be expected to change incidence.45
There have been two prospective epidemiological studies of mortality among cannabis users. A Swedish study of mortality during 15 years among male military conscripts showed an increased risk of premature death among men who had smoked cannabis 50 or more times by age 18.49 Violent and accidental death was the main contributor to this excess. However, the association between mortality and cannabis use disappeared after multivariate statistical adjustment for alcohol and other drug use.49
Sydney and colleagues50 reported a 10-year study of mortality in cannabis users aged between 15 and 49 years among 65171 members of the Kaiser Permanente Medical Care Program. The sample consisted of 38% who had never used cannabis, 20% who had used fewer than six times, 20% who were former users, and 22% who were current users. Regular cannabis use had a small association with premature mortality (RR 1.33), which was wholly explained by increased deaths from AIDS in men, probably because marijuana use was a marker for male homosexual behaviour in this cohort. It is too early to conclude from the study that marijuana use does not increase mortality because the average age at follow-up was only 43 years, and cigarette smoking and alcohol use were only modestly associated with premature mortality.50
Possible effects of increased THC content of cannabis The average THC content of cannabis has probably increased over the past several decades, but without good data by how much is unclear.2 This situation probably reflects a combination of an increased market for more potent cannabis products among regular users,2 and improved methods of growing high-THC-content.3 The net health consequences of any increase in potency are uncertain.2 Among naïve users, higher THC content may increase adverse psychological effects, including psychotic symptoms, thereby discouraging some from continuing to use. Among those who continue to use cannabis, increased potency may increase the risks of developing dependence, having accidents if driving while intoxicated, and experiencing psychotic symptoms. If experienced users can regulate their dose of THC, the respiratory risks of cannabis smoking may be marginally reduced.
Health advice for cannabis users
Uncertainty about the adverse health effects of acute, and especially chronic, cannabis use, should not prevent medical practitioners from advising patients who use cannabis about the most probable ill-effects of their cannabis use with emphasis on the uncertainty. In the absence of other risk factors, this should include advice about the possibility of being involved in a motor-vehicle accident if patients drive while intoxicated by cannabis; the higher risk of an accident if they drive when intoxicated by both alcohol and cannabis; the respiratory risks of long-term cannabis smoking, which are substantially increased if they also smoke tobacco; an increased risk of developing dependence if they are daily users of cannabis; and the possibility of subtle cognitive impairment if they use regularly over several years.
We thank Greg Chesher for comments on an earlier version of this manuscript.
1 Hall W, Johnston L, Donnelly N. The epidemiology of cannabis use and its consequences. In: Kalant H, Corrigal W, Hall W, Smart R, eds. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
5 Kandel DB, Davies M. Progression to regular marijuana involvement: phenomenology and risk factors for near daily use. In: Glantz M, Pickens R, eds. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992.
6 Chait LD, Pierri J. Effects of smoked marijuana on human performance: a critical review. In: Murphy A, Bartke J, eds. Marijuana/cannabinoids: neurobiology and neurophysiology. Boca Raton: CRC, 1992.
9 Chesher G. Cannabis and road safety: an outline of research studies to examine the effects of cannabis on driving skills and actual driving performance. In: Road Safety Committee, Parliament of Victoria. The effects of drugs (other than alcohol) on road safety. Melbourne: Road Safety Committee, Parliament of Victoria, 1995: 67-96.
10 Leuchtenberger C. Effects of marihuana (cannabis) smoke on cellular biochemistry of in vitro test systems. In: Fehr KO, Kalant H, eds. Cannabis and health hazards. Toronto: Addiction Research Foundation, 1983.
13 Coates RA, Farewell VT, Raboud J, et al. Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease. Am J Epidemiol 1990; 132: 717-22.
14 Kaslow RA, Blackwelder WC, Ostrow DG, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals: a report from the Multicentre AIDS Cohort Study. JAMA 1989; 261: 3424-29.
16 Tashkin DP, Fligiel S, Wu TC, et al. Effects of habitual use of marijuana and/or cocaine on the lung. In: Chiang CN, Hawks RL, eds. Research findings on smoking of abused substances. National Institute on Drug Abuse Research Monograph 99. Rockville, Maryland: National Institute on Drug Abuse, 1990.
23 Bloch E. Effects of marijuana and cannabinoids on reproduction, endocrine function, development and chromosomes. In: Fehr KO, Kalant H, eds. Cannabis and health hazards. Toronto: Addiction Research Foundation, 1983.
24 Abel EL. Effects of prenatal exposure to cannabinoids. In: Pinkert TM, ed. Current research on the consequences of maternal drug abuse. NIDA Research Monograph no 59. Washington: Department of Health and Human Services, 1985.
25 Richardson GA, Day NL, McGauhey PJ. The impact of prenatal marijuana and cocaine use on the infant and child. Clin Obstet Gynecol 1993; 36: 302-18. 26 Fried PA. Prenatal exposure to tobacco and marijuana: effects during pregnancy, infancy and early childhood. Clin Obstet Gynecol 1993; 36: 319-36.
29 Fried PA. Behavioural outcomes in preschool-aged children exposed prenatally to marijuana: a review and speculative interpretation. In: Wetherington CL, Smeriglio CL, Finnegan L, eds. Behavioural studies of drug exposed offspring: methodological issues in human and animal research. NIDA Research Monograph 164. Washington DC: US Government Printing Office, 1996.
30 Robison LI, Buckley JD, Daigle AE, et al. Maternal drug use and the risk of childhood nonlympholastic leukemia among offspring: an epidemiologic investigation implicating marijuana. Cancer 1989; 63: 1904-11.
40 Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhabitants: basic findings from the National Comorbidity Study. Clin Exp Psychopharmacol 1994; 2: 244-68.
49 Andreasson S, Allebeck P. Cannabis and mortality among young men: a longitudinal study of Swedish conscripts. Scand J Social Med 1990; 18: 9-15. 50 Sidney S, Beck JE, Tekawa IE, et al. Marijuana use and mortality. Am J Public Health 1997; 87: 585-90.
Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. National Drug Strategy Monograph Series no 25. Canberra: Australian Government Publishing Service, 1994.
Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20.
Kalant H, Corrigal W, Hall W, Smart R, eds. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
Programme on Substance Abuse, WHO. Cannabis: a health perspective and research agenda. Geneva: Division of Mental Health and Prevention of Substance Abuse, WHO, 1997.
Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1585-614.
Compton DR, Harris LS, Lichtman AH, Martin BR. Marihuana. In: Schuster CR, Kuher MJ, eds. Pharmacological aspects of drug dependence. Berlin: Springer Verlag, 1993,
Pertwee RG. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors: an overview. In: Pertwee RG, ed. Cannabinoid receptors. London: Harcourt Brace, 1995.
Patterns of cannabis use
Bachman JG, Wadsworth KN, O'Malley PM, et al. Smoking, drinking and drug use in young adulthood: Malwah, New Jersey: Lawrence Erlbaum Associates, 1997.
Hall W, Johnston L, Donnelly N. The epidemiology of cannabis use and its consequences. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
Chesher G. Cannabis and road safety: an outline of research studies to examine the effects of cannabis on driving skills and actual driving performance. In: Road Safety Committee, Parliament of Victoria. The effects of drugs (other than alcohol) on road safety. Melbourne: Road Safety Committee, Parliament of Victoria, 1995: 67-96.
Robbe HWJ. Influence of marijuana on driving. Maastricht, Institute for Human Psychopharmacology, University of Limberg, 1994.
Smiley A. Marijuana: on road and driving simulator studies. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
Terhune KW. Problems and methods in studying drug crash effects. Alcohol Drugs Driving 1986; 2: 1-13.
Hollister LE. Marijuana and immunity. J Psychoactive Drugs 1992; 24: 159-64. Klein TW. Cannabis and immunity. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
Tashkin D. Effects of cannabis on the respiratory system. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
Taylor FM. Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South Med J 1988; 81: 1213-16.
Wu T, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988; 318: 347-51.
Fried PA. Prenatal exposure to tobacco and marijuana: effects during pregnancy, infancy and early childhood. Clin Obstet Gynecol 1993; 36: 319-36.
Fried PA. The Ottawa Prenatal Prospective Study (OPPS): methodological issues and findings-its easy to throw the baby out with the bath water. Life Sci 1995; 56: 2159-68.
Richardson GA, Day NL, McGauhey PH. The impact of prenatal marijuana and cocaine use on the infant and child. Clin Obstet Gynecol 1993; 36: 302-18. Adolescent use
Chen K, Kandel DB. The natural history of drug use from adolescence to the mid-thirties in a general population sample. Am J Public Health 1995; 85: 41-47.
Hall W, Johnston L, Donnelly N. The epidemiology of cannabis use and its consequences. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
Kandel DB. Issues of sequencing of adolescent drug use and other problem behaviors. Drugs Soc 1988; 3: 55-76.
Osgood DW, Johnston LD, O'Malley PM, Bachman JG. The generality of deviance in late adolescence and early adulthood. Am Social Rev 1988; 53: 81-93.
Channabasavanna S, Paes M, Hall W. Psychiatric and behavioural effects of cannabis. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Reseach Foundation, 1998.
Jones RT, Benowitz N, Herning RI. The clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21: 143S-152S.
Stephens RS, Roffman RA. Adult marijuana dependence. In: Baer JS, Marlatt GA, MacMahon RJ, eds. Addictive behaviors across the lifespan: prevention, treatment and policy issues. Newbury Park, California: Sage Publications, 1993.
Pope HG, Gruber AJ, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend 1995; 38: 25-34.
Solowij N. Cannabis and cognitive functioning. Cambridge: Cambridge University Press, 1998.
Allebeck P. Cannabis and schizophrenia: is there a causal association? In: Nahas GG, Latour C, eds. Physiopathology of illicit drugs: cannabis, cocaine, opiates. Oxford: Pergamon Press, 1991.
Channabasavanna S, Paes M, Hall W. Psychiatric and behavioural effects of cannabis. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Research Foundation, 1998.
Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993; 163: 141-49.
Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Mental Disorder 1990; 178: 473-80.
Thornicroft G. Cannabis and psychosis: is there epidemiological evidence for an association? Br J Psychiatry 1990; 157: 25-33.
British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic, 1997.
Hartel C. Therapeutic uses of cannabis. In: Kalant H, Corrigal W, Hall W, Smart R. The health effects of cannabis. Toronto: Addiction Research Foundaton, 1998.
National Institute on Drug Abuse. Report on the possible medical uses of marijuana. Washington, DC: National Institutes of Health, 1997.
Pubdate: Sat, 14 Nov 1998 Source: Lancet, The (UK) Volume: 352, Number 9140 Contact: email@example.com Website: http://www.thelancet.com/ Copyright: Lancet, The (UK) Author: Wayne Hall, Nadia Solowij